Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;17(4):3129-3135.
doi: 10.3892/etm.2019.7286. Epub 2019 Feb 19.

Correlation of miR-21 and BNP with pregnancy-induced hypertension complicated with heart failure and the diagnostic value

Affiliations

Correlation of miR-21 and BNP with pregnancy-induced hypertension complicated with heart failure and the diagnostic value

Changli Kan et al. Exp Ther Med. 2019 Apr.

Abstract

Correlation of miR-21 and B-type natriuretic peptide (BNP) with pregnancy-induced hypertension (PIH) complicated with heart failure and the diagnostic value was investigated. Sixty patients with PIH complicated with heart failure admitted to Affiliated Hospital of Chengde Medical University from July 2016 to July 2017 were enrolled as the experimental group, and 35 normal pregnant women as the control group. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) method was used to determine the expression level of plasma miR-21 expression level. An automatic biochemical analyzer was used to determine plasma BNP expression level. Spearmans correlation analysis was used for the correlation analysis of miR-21 and BNP. ROC curve was used for evaluating the diagnostic values of miR-21 and BNP for PIH complicated with heart failure. miR-21 and BNP expression levels were higher in patients with PIH complicated with heart failure than those in the normal individuals, and were increased in line with the heart failure grade (P<0.001). The plasma miR-21 expression was positively correlated with BNP in patients with PIH complicated with heart failure (r=0.685, P<0.001). Both miR-21 and BNP had higher diagnostic values for PIH complicated with heart failure, in the diagnosis, the best cut-off value [odds ratio (OR)] of miR-21 was 1.113, with an area under curve (AUC) of 0.889 and a 95% confidence interval (CI) of 82.05-95.76%; the OR of BNP was 123, with an AUC of 0.747 and a 95% CI of 64.95-84.38%. Blood pressure, six-minute walk test (6MWT), left ventricular ejection fraction (LVEF) and left ventricular end diastolic diameter (LVEDD) were independent risk factors for the occurrence of PIH complicated with heart failure (P<0.05). In conclusion, miR-21 and BNP, highly expressed in patients with PIH complicated with heart failure, are expected to become important biomarkers for diagnosing PIH complicated with heart failure and judging the degree of heart failure in the patients, and worthy of clinical popularization and application.

Keywords: B-type natriuretic peptide; heart failure; miR-21; pregnancy-induced hypertension.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Diagnostic value of miR-21 and BNP for PIH complicated with heart failure. The analysis of ROC curve showed that in the diagnosis of PIH complicated with heart failure, the OR of miR-21 was 1.113, the sensitivity was 88.53% and the specificity was 88.33%, with an AUC of 0.889 and a 95% CI of 82.05–95.76%; the OR of BNP cut-off value was 123, the sensitivity was 88.57% and the specificity was 63.33%, with an AUC of 0.747 and a 95% CI of 64.95–84.38%. BNP, B-type natriuretic peptide; PIH, pregnancy-induced hypertension; ROC, receiver operating characteristic; AUC, area under curve; CI, confidence interval; OR, odds ratio.
Figure 2.
Figure 2.
Correlation analysis of miR-21 expression with BNP in PIH complicated with heart failure. The plasma miR-21 expression was positively correlated with BNP in patients with PIH complicated with heart failure (r=0.685, P<0.001). BNP, B-type natriuretic peptide; PIH, pregnancy-induced hypertension.

References

    1. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;10:CD002252. - PMC - PubMed
    1. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Magee LA, Audibert F, Bujold E, Côté A-M, Douglas MJ, et al. Canadian Hypertensive Disorders of Pregnancy Working Group Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: Executive summary. J Obstet Gynaecol Can. 2014;36:416–441. doi: 10.1016/S1701-2163(15)30588-0. - DOI - PubMed
    1. Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: Systematic review and meta-analysis. BMJ. 2014;348:g2301. doi: 10.1136/bmj.g2301. - DOI - PMC - PubMed
    1. Gini R, Schuemie MJ, Mazzaglia G, Lapi F, Francesconi P, Pasqua A, Bianchini E, Montalbano C, Roberto G, Barletta V, et al. Automatic identification of type 2 diabetes, hypertension, ischaemic heart disease, heart failure and their levels of severity from Italian General Practitioners electronic medical records: A validation study. BMJ Open. 2016;6:e012413. doi: 10.1136/bmjopen-2016-012413. - DOI - PMC - PubMed
    1. Li Z, Rana TM. Therapeutic targeting of microRNAs: Current status and future challenges. Nat Rev Drug Discov. 2014;13:622–638. doi: 10.1038/nrd4359. - DOI - PubMed

LinkOut - more resources